MPH Stock Overview
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Medicure Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$1.20 |
52 Week High | CA$1.80 |
52 Week Low | CA$0.93 |
Beta | 1.01 |
1 Month Change | 8.11% |
3 Month Change | -11.11% |
1 Year Change | 20.00% |
3 Year Change | -22.08% |
5 Year Change | -80.65% |
Change since IPO | -88.89% |
Recent News & Updates
Recent updates
Investors Don't See Light At End Of Medicure Inc.'s (CVE:MPH) Tunnel
Mar 08We Ran A Stock Scan For Earnings Growth And Medicure (CVE:MPH) Passed With Ease
Aug 28Medicure's (CVE:MPH) Earnings Are Weaker Than They Seem
Nov 30Here's Why Shareholders Should Examine Medicure Inc.'s (CVE:MPH) CEO Compensation Package More Closely
Jun 15Shareholder Returns
MPH | CA Biotechs | CA Market | |
---|---|---|---|
7D | 4.3% | 1.4% | 0.4% |
1Y | 20.0% | -26.0% | 9.0% |
Return vs Industry: MPH exceeded the Canadian Biotechs industry which returned -28.6% over the past year.
Return vs Market: MPH exceeded the Canadian Market which returned 9% over the past year.
Price Volatility
MPH volatility | |
---|---|
MPH Average Weekly Movement | 19.2% |
Biotechs Industry Average Movement | 12.4% |
Market Average Movement | 8.5% |
10% most volatile stocks in CA Market | 18.4% |
10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: MPH has not had significant price volatility in the past 3 months.
Volatility Over Time: MPH's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | n/a | Albert Friesen | https://www.medicure.com |
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia.
Medicure Inc. Fundamentals Summary
MPH fundamental statistics | |
---|---|
Market cap | CA$12.52m |
Earnings (TTM) | CA$1.08m |
Revenue (TTM) | CA$22.94m |
11.6x
P/E Ratio0.5x
P/S RatioIs MPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MPH income statement (TTM) | |
---|---|
Revenue | CA$22.94m |
Cost of Revenue | CA$6.96m |
Gross Profit | CA$15.98m |
Other Expenses | CA$14.90m |
Earnings | CA$1.08m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.10 |
Gross Margin | 69.68% |
Net Profit Margin | 4.71% |
Debt/Equity Ratio | 0% |
How did MPH perform over the long term?
See historical performance and comparison